Saratin for inhibiting platelet adhesion to collagen

US6881722B2 · kind B2 · utility

Assignee

• MERCK & CO., INC. · US

Inventors

• Christopher Barnes · Bad Soden, DE
• Matthias Frech · Basel, CH
• Uwe Hofmann · Würzburg, DE
• Johannes Gleitz · Darmstadt, DE
• Wolfgang Strittmatter · Ober-Ramstadt, DE

Key dates

• Filing date: Aug 23, 2001
• Grant date: Apr 19, 2005
• Expiry date: Aug 23, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61M2025/0057
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Use of the polypeptide Saratin for the manufacture of a medicament having the capability to significantly decrease platelet adhesion and platelet accumulation after vascular injuries or endarterectomy. The invention furthermore relates to a novel medical use of Saratin as an inhibitor of thrombosis and intimal hyperplasia, wherein the Saratin polypeptide may be used locally as a topical agent or as a coating on, or otherwise incorporated or associated with medical devices.